Section of Hematology / Oncology
Professor of Medicine
Leon O. Jacobson Professor of Medicine;Director, Center for Personalized Therapeutics;
Associate Director for Clinical Sciences, Comprehensive Cancer Center
Referring Physician Access Line: 1-877-DOM-2730
|BA||1976||Harvard University||Biochemical Sciences
|Residency||1983||Johns Hopkins University||Internal Medicine
|Fellowship||1986||The University of Chicago||Hematology/Oncology
Dr. Ratain is interested in the pharmacogenetics of anticancer agents and phase I and phase II drug studies. Dr. Ratain’s research is focused on the metabolism of specific anticancer agents. He has demonstrated the critical importance of genetic variants in determining variability in the pharmacogenetics and toxicity of certain anticancer drugs. His research has become a model for understanding variability in response to newer targeted drugs.
New drug development, phase I and phase II drug development, advanced solid tumors.
- Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Ratain MJ. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101, 847-854 (1998).
- Rosner GL, Stadler W, Ratain MJ. The randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20, 4478-4484 (2002).
- Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H, Ratain MJ, DiRienzo A. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12, 725-733 (2002).
- Liu W, Innocenti F, Das S, Chen P, Cook EH, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 9, 1009-1012 (2003).
- Innocenti F, Undevia SD, Iyer L, Chen P, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronsyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22, 1382-1388 (2004).